2seventy bio Inc. (TSVT): Price and Financial Metrics
GET POWR RATINGS... FREE!
TSVT POWR Grades
- Growth is the dimension where TSVT ranks best; there it ranks ahead of 80.22% of US stocks.
- TSVT's strongest trending metric is Value; it's been moving down over the last 177 days.
- TSVT ranks lowest in Momentum; there it ranks in the 5th percentile.
TSVT Stock Summary
- With a one year PEG ratio of 0.49, 2SEVENTY BIO INC is expected to have a higher PEG ratio (a measure of how expensive a stock is relative to its expected earnings growth) than just 4.17% of US stocks.
- 2SEVENTY BIO INC's stock had its IPO on November 5, 2021, making it an older stock than just 0.9% of US equities in our set.
- With a year-over-year growth in debt of 139.1%, 2SEVENTY BIO INC's debt growth rate surpasses 90.65% of about US stocks.
- Stocks with similar financial metrics, market capitalization, and price volatility to 2SEVENTY BIO INC are MRUS, RAPT, AGIO, VXRT, and RARE.
- To check out 2SEVENTY BIO INC's SEC filings, go to the company's page on browse-edgar?action=getcompany&CIK=0001860782.
TSVT Valuation Summary
- In comparison to the median Healthcare stock, TSVT's EV/EBIT ratio is 121.67% lower, now standing at -2.2.
- Over the past 15 months, TSVT's price/sales ratio has gone up 6.3.
Below are key valuation metrics over time for TSVT.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| TSVT | 2023-01-30 | 9.5 | 1.5 | -1.7 | -2.2 |
| TSVT | 2023-01-27 | 9.8 | 1.6 | -1.7 | -2.2 |
| TSVT | 2023-01-26 | 9.5 | 1.5 | -1.7 | -2.2 |
| TSVT | 2023-01-25 | 9.4 | 1.5 | -1.7 | -2.2 |
| TSVT | 2023-01-24 | 9.0 | 1.4 | -1.6 | -2.1 |
| TSVT | 2023-01-23 | 8.4 | 1.3 | -1.5 | -2.0 |
TSVT Stock Price Chart Interactive Chart >
TSVT Price/Volume Stats
| Current price | $14.98 | 52-week high | $19.33 |
| Prev. close | $14.13 | 52-week low | $8.44 |
| Day low | $14.16 | Volume | 681,845 |
| Day high | $15.25 | Avg. volume | 647,644 |
| 50-day MA | $12.02 | Dividend yield | N/A |
| 200-day MA | $13.70 | Market Cap | 568.00M |
2seventy bio Inc. (TSVT) Company Bio
2seventy Bio, Inc. operates as cell and gene therapy company. It is focused on the research, development, and commercialization of transformative treatments for cancer. The company was founded on April 26, 2021 and is headquartered in Cambridge, MA.
Latest TSVT News From Around the Web
Below are the latest news stories about 2SEVENTY BIO INC that investors may wish to consider to help them evaluate TSVT as an investment opportunity.
2seventy bio to Participate in Upcoming Investor ConferencesCAMBRIDGE, Mass., February 01, 2023--2seventy bio, Inc. (Nasdaq: TSVT) announced today that members of the management team will participate in the following upcoming investor conferences: |
Medigene Receives $3 Million Milestone Payment from 2seventy bioMilestone payment is related to the establishment of 2seventy bio’s strategic partnership with JW TherapeuticsPayment provides further validation of Medigene’s end-to-end platform MARTINSRIED, Germany and MUNICH, Germany, Jan. 18, 2023 (GLOBE NEWSWIRE) -- Martinsried -- Medigene AG (Medigene, FSE: MDG1, Prime Standard), an immuno-oncology company focused on the development of differentiated, best-in-class T Cell Receptor engineered T cell (TCR-T) therapies, today announced that it has received a |
2seventy bio Provides Company Outlook for 2023CAMBRIDGE, Mass., January 09, 2023--2seventy bio, Inc. (Nasdaq: TSVT) announced today key corporate milestones and financial outlook for 2023. |
2seventy bio Announces Expanded Translational Collaboration with Regeneron to Develop New Cell Therapy-Based Combinations for Solid TumorsCAMBRIDGE, Mass.--(BUSINESS WIRE)--2seventy bio, Inc. (Nasdaq: TSVT) today announced an amendment to its collaboration with Regeneron that will facilitate an expanded and accelerated development plan for novel cell therapy-based combinations for solid tumors. The collaboration will leverage 2seventy bio’s unique cell therapy engineering and early-stage development capabilities, including the newly built in-house clinical cell therapy manufacturing facility, with Regeneron’s differentiated antib |
How should investors view 2seventy bio Inc. (TSVT)?The share price of 2seventy bio Inc. (NASDAQ:TSVT) rose to $8.96 per share on Thursday from $8.57. While 2seventy bio Inc. has overperformed by 4.55%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, TSVT fell by -66.63%, with highs and lows ranging from $28.00 to $8.44, […] |
TSVT Price Returns
| 1-mo | 49.95% |
| 3-mo | -7.64% |
| 6-mo | -13.01% |
| 1-year | -3.85% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | 59.87% |
| 2022 | -63.44% |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
Loading social stream, please wait...